News | November 16, 2025
Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Subscribe To Our Newsletter & Stay Updated
